Physicians' Academy for Cardiovascular Education

Effects of SGLT2i are not modified by gout history in patients with HF

Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER

Literature - Butt JH, Docherty KF, Claggett BL, et al. - JAMA Cardiol. 2023 Apr 1;8(4):386-393. doi: 10.1001/jamacardio.2022.5608.

Introduction and methods


Gout is common in patients with HF and associated with adverse clinical outcomes [1-5]. SGLT2i therapy reduces uric acid levels, and therefore may reduce the risk of gout [6-8].

Aim of the study

The authors investigated the association between gout and clinical outcomes in patients with HF. Moreover, the effect of dapagliflozin in patients with HF with and without gout were examined, as well as the effect of dapagliflozin on the introduction of new uric-acid lowering therapy and colchicine in these patients.


This was a pooled post hoc analysis of 2 phase 3 clinical trials with dapagliflozin which included 11,005 patients with HF. Data of the DAPA-HF and DELIVER trials, which were randomized, double-blind, clinical trials with patients with symptomatic HF and elevated natriuretic peptide levels, were used. Patients with LVEF of ≤40% were enrolled in DAPA-HF, and patients with LVEF of >40% in DELIVER. Patients received dapagliflozin (10 mg) once daily or placebo. A total of 117 patients (10.1%) had a history of gout at baseline (10.3% with LVEF ≤40% and 10.2% with LVEF >40%). History of gout was investigator-reported.


The primary outcome was the composite of worsening HF or CV death.

Main results

Gout and clinical outcomes

Effects of dapagliflozin


This pooled analysis demonstrated that dapagliflozin has beneficial effects on CV outcomes in patients with HF irrespective of gout status. Moreover, dapagliflozin use was associated with a lower initiation of new uric-acid lowering therapies or colchicine.


Show references

Find this article online at JAMA Cardiol.

Share this page with your colleagues and friends: